BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Jeet V, Tevz G, Lehman M, Hollier B, Nelson C. Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer 2014;21:723-37. [PMID: 24981110 DOI: 10.1530/ERC-14-0267] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
2 Nøjgaard C, Johansen JS, Bjerregaard P, Bojesen SE, Becker U. Plasma YKL-40 in Inuit and Danes. Alcohol Alcohol 2015;50:11-7. [PMID: 25332349 DOI: 10.1093/alcalc/agu072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 2021;247:104329. [PMID: 34298186 DOI: 10.1016/j.jprot.2021.104329] [Reference Citation Analysis]
4 Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 2014;9:e87746. [PMID: 24498368 DOI: 10.1371/journal.pone.0087746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
5 Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One 2014;9:e95822. [PMID: 24752554 DOI: 10.1371/journal.pone.0095822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol. 2011;70:163-169. [PMID: 21391238 DOI: 10.1002/ana.22360] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
7 Harving ML, Christensen LH, Ringsholt M, Lausten GS, Petersen MM. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop 2014;85:195-200. [PMID: 24650028 DOI: 10.3109/17453674.2014.893496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. Proc Am Thorac Soc 2012;9:74-9. [PMID: 22550249 DOI: 10.1513/pats.201107-039MS] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
9 Qin G, Li X, Chen Z, Liao G, Su Y, Chen Y, Zhang W. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis. Mol Neurobiol 2017;54:3264-70. [PMID: 27090900 DOI: 10.1007/s12035-016-9878-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
10 Song CL, Bin-Li, Diao HY, Wang JH, Shi YF, Lu Y, Wang G, Guo ZY, Li YX, Liu JG, Wang JP, Zhang JC, Zhao Z, Liu YH, Li Y, Cai D, Li Q. Diagnostic Value of Serum YKL-40 Level for Coronary Artery Disease: A Meta-Analysis. J Clin Lab Anal 2016;30:23-31. [PMID: 27152377 DOI: 10.1002/jcla.21804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Fuksiewicz M, Kotowicz B, Rutkowski A, Achinger-Kawecka J, Wagrodzki M, Kowalska MM. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis. Technol Cancer Res Treat 2018;17:1533033818765209. [PMID: 29642772 DOI: 10.1177/1533033818765209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Baroke E, Gauldie J, Kolb M. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Expert Rev Respir Med 2013;7:465-78. [PMID: 24138691 DOI: 10.1586/17476348.2013.838015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
13 Wang HL, Hsiao PC, Tsai HT, Yeh CB, Yang SF. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients. Int J Mol Sci 2013;14:22817-25. [PMID: 24256818 DOI: 10.3390/ijms141122817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
14 Sørensen AK, Holmgaard DB, Mygind LH, Johansen J, Pedersen C. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study. J Inflamm (Lond) 2015;12:20. [PMID: 25908927 DOI: 10.1186/s12950-015-0064-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
15 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
16 Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011;105:106-13. [PMID: 20888745 DOI: 10.1016/j.rmed.2010.09.012] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
17 Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 2016;26:367-76. [PMID: 27076041 DOI: 10.1097/CMR.0000000000000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
18 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
19 Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; Nordic Myeloma Study Group. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. Leuk Lymphoma 2015;56:2650-9. [PMID: 25573204 DOI: 10.3109/10428194.2015.1004168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
20 Krecak I, Gveric-Krecak V, Roncevic P, Basic-Kinda S, Gulin J, Lapic I, Fumic K, Ilic I, Horvat I, Zadro R, Holik H, Coha B, Peran N, Aurer I, Durakovic N. Serum chitotriosidase: a circulating biomarker in polycythemia vera. Hematology 2018;23:793-802. [PMID: 29993340 DOI: 10.1080/10245332.2018.1498157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ma B, Herzog EL, Moore M, Lee CM, Na SH, Lee CG, Elias JA. RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Sci Rep 2016;6:26299. [PMID: 27198666 DOI: 10.1038/srep26299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kornblit B, Hellemann D, Munthe-Fog L, Bonde J, Strøm JJ, Madsen HO, Johansen JS, Garred P. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology 2013;218:1227-34. [PMID: 23706599 DOI: 10.1016/j.imbio.2013.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. J Gynecol Oncol 2021;32:e18. [PMID: 33327048 DOI: 10.3802/jgo.2021.32.e18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, Andersen CY, Møllgård K. YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 2012;60:188-204. [PMID: 22140133 DOI: 10.1369/0022155411433331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE. Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet 2013;50:831-7. [PMID: 24062521 DOI: 10.1136/jmedgenet-2013-101908] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
26 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
27 Urbanavičiūtė R, Skauminas K, Skiriutė D. The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis. Brain Sci 2020;10:E872. [PMID: 33227903 DOI: 10.3390/brainsci10110872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Peng H, Su Q, Lin ZC, Zhu XH, Peng MS, Lv ZB. Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression. Oncol Lett 2018;15:7403-8. [PMID: 29731892 DOI: 10.3892/ol.2018.8220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Izaguirre M, Hernández-Lizoain JL, Baixauli J, Martí P, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G. Increased Obesity-Associated Circulating Levels of the Extracellular Matrix Proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C Are Associated with Colon Cancer. PLoS One 2016;11:e0162189. [PMID: 27612200 DOI: 10.1371/journal.pone.0162189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
30 Nielsen TL, Plesner LL, Warming PE, Pallisgaard JL, Dalsgaard M, Schou M, Høst U, Rydahl C, Brandi L, Køber L, Johansen JS, Kastrup J, Iversen KK. YKL-40 in patients with end-stage renal disease receiving haemodialysis. Biomarkers 2018;23:357-63. [DOI: 10.1080/1354750x.2018.1428359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
31 Jönsson M, Gerdle B, Ghafouri B, Bäckryd E. The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study. BMC Neurosci 2021;22:6. [PMID: 33522900 DOI: 10.1186/s12868-021-00608-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract 2012;96:84-9. [PMID: 22209020 DOI: 10.1016/j.diabres.2011.12.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
33 Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics 2018;8:4409-28. [PMID: 30214629 DOI: 10.7150/thno.26467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
34 Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2016;34:257.e19-24. [DOI: 10.1016/j.urolonc.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, Hsieh SF, Chen CA, Cheng WF. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget 2015;6:39740-55. [PMID: 26452028 DOI: 10.18632/oncotarget.5469] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
36 Tong X, Wang D, Liu S, Ma Y, Li Z, Tian P, Fan H. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis 2018;13:409-18. [PMID: 29430175 DOI: 10.2147/COPD.S152655] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
37 Skorupa A, Urbach S, Vigy O, King MA, Chaumont-dubel S, Prehn JH, Marin P. Angiogenin induces modifications in the astrocyte secretome: Relevance to amyotrophic lateral sclerosis. Journal of Proteomics 2013;91:274-85. [DOI: 10.1016/j.jprot.2013.07.028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
38 Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205. [PMID: 22095223 DOI: 10.1038/bjc.2011.501] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
39 Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011;13:1244-1251. [PMID: 21831900 DOI: 10.1093/neuonc/nor117] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
40 Jensen P, Wiell C, Milting K, Poggenborg R, Østergaard M, Johansen J, Skov L. Plasma YKL-40: a potential biomarker for psoriatic arthritis?: Plasma YKL-40 in psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology 2013;27:815-9. [DOI: 10.1111/j.1468-3083.2012.04570.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
41 Sørensen MS, Colding-Rasmussen T, Horstmann PF, Hindsø K, Dehlendorff C, Johansen JS, Petersen MM. Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities. Cancers (Basel) 2021;13:2833. [PMID: 34200156 DOI: 10.3390/cancers13112833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Parisi GF, Papale M, Tardino L, Nenna R, Midulla F, Leonardi S. Biomarkers in Pediatric Lung Diseases Including Cystic Fibrosis. CRMR 2020;15:163-73. [DOI: 10.2174/1573398x15666190521112824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int 2011;10:605-10. [PMID: 22146624 DOI: 10.1016/s1499-3872(11)60103-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
44 Wan G, Xiang L, Sun X, Wang X, Li H, Ge W, Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget 2017;8:5382-91. [PMID: 28036271 DOI: 10.18632/oncotarget.14280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
45 Shaker OG, Elbaz EM. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females. Asian Pac J Cancer Prev 2020;21:355-61. [PMID: 32102511 DOI: 10.31557/APJCP.2020.21.2.355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Ziatabar S, Zepf J, Rich S, Danielson BT, Bollyky PI, Stern R. Chitin, chitinases, and chitin lectins: Emerging roles in human pathophysiology. Pathophysiology 2018;25:253-62. [PMID: 30266339 DOI: 10.1016/j.pathophys.2018.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
47 Nada D, Julien C, Rompré PH, Akoume MY, Gorman KF, Samuels ME, Levy E, Kost J, Li D, Moreau A. Association of Circulating YKL-40 Levels and CHI3L1 Variants with the Risk of Spinal Deformity Progression in Adolescent Idiopathic Scoliosis. Sci Rep 2019;9:5712. [PMID: 30952886 DOI: 10.1038/s41598-019-41191-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
49 Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res 2015;4:287-91. [PMID: 26207216 DOI: 10.3978/j.issn.2218-6751.2015.04.04] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
50 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010;68:903-12. [PMID: 21035623 DOI: 10.1016/j.biopsych.2010.08.025] [Cited by in Crossref: 240] [Cited by in F6Publishing: 241] [Article Influence: 21.8] [Reference Citation Analysis]
51 Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol 2016;140:64-9. [PMID: 26607777 DOI: 10.1016/j.ygyno.2015.11.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
52 Linhares P, Carvalho B, Vaz R, Costa BM. Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance? Int J Mol Sci 2020;21:E5809. [PMID: 32823572 DOI: 10.3390/ijms21165809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
53 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
54 Bjørnbak C, Brøchner CB, Larsen LA, Johansen JS, Møllgård K. Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem 2014;62:369-88. [PMID: 24595665 DOI: 10.1369/0022155414528514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
55 Xavier-Magalhães A, Nandhabalan M, Jones C, Costa BM. Molecular prognostic factors in glioblastoma: state of the art and future challenges. CNS Oncol 2013;2:495-510. [PMID: 25054820 DOI: 10.2217/cns.13.48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
56 Nielsen KR, Steffensen R, Bendtsen MD, Rodrigo-Domingo M, Baech J, Haunstrup TM, Bergkvist KS, Schmitz A, Boedker JS, Johansen P, Dybkaeær K, Boeøgsted M, Johnsen HE. Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival. PLoS One 2015;10:e0139329. [PMID: 26448050 DOI: 10.1371/journal.pone.0139329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
57 Andersen CL, Bjørn ME, Mcmullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 2014;38:816-21. [DOI: 10.1016/j.leukres.2014.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tang Y, Qing C, Wang J, Zeng Z. DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma. Cell Transplant 2020;29:963689720933241. [PMID: 32510239 DOI: 10.1177/0963689720933241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Bjørn ME, Andersen CL, Jensen MK, Hasselbalch HC. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. Eur J Haematol 2014;93:224-8. [DOI: 10.1111/ejh.12332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
60 Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2013;13:77. [PMID: 24373580 DOI: 10.1186/1471-2466-13-77] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
61 Bulanık M, Sağsöz N, Sayan CD, Yeral Mİ, Kısa Ü. Comparison of Serum Ykl-40 and Ischemia Modified Albulmin Levels Between Pregnant Women with Hyperemesis Gravidarum and Normal Pregnant Women. Med Arch 2019;73:97-100. [PMID: 31391695 DOI: 10.5455/medarh.2019.73.97-100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
63 Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, Hetland ML, Krintel SB, Johnsen HE, Nyegaard M, Johansen JS. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 2011;13:R109. [PMID: 21714862 DOI: 10.1186/ar3391] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
64 Kumar A, Zhang KYJ. Human Chitinases: Structure, Function, and Inhibitor Discovery. Adv Exp Med Biol 2019;1142:221-51. [PMID: 31102249 DOI: 10.1007/978-981-13-7318-3_11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
65 Jin Y, Cao JN, Wang CX, Feng QT, Ye XH, Xu X, Yang CJ. High serum YKL-40 level positively correlates with coronary artery disease. Biomark Med 2017;11:133-9. [PMID: 28097894 DOI: 10.2217/bmm-2016-0240] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
66 Guo W, Wang J, Wei H. Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas. Reprod Sci 2016;23:1559-64. [DOI: 10.1177/1933719116648219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
67 Hillmeister P, Buschmann E, Persson PB, Bondke Persson A. Exercise for healthy flow. Acta Physiol 2017;219:3-8. [DOI: 10.1111/apha.12831] [Reference Citation Analysis]
68 Gybel-Brask D, Høgdall E, Johansen J, Christensen IJ, Skibsted L. Serum YKL-40 and uterine artery Doppler -- a prospective cohort study, with focus on preeclampsia and small-for-gestational-age. Acta Obstet Gynecol Scand 2014;93:817-24. [PMID: 24861484 DOI: 10.1111/aogs.12432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas 2020;49:53-61. [PMID: 31856080 DOI: 10.1097/MPA.0000000000001466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
70 Itik V, Kemik O, Kemik A, Dulger AC, Sümer A, Soyoral YU, Begenik H, Purisa S, Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer 2011;3:25-30. [PMID: 24179388 DOI: 10.4137/BIC.S7154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
71 Nielsen HJ, Jakobsen KV, Christensen IJ, Brünner N; Danish Study Group on Early Detection of Colorectal Cancer. Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol 2011;46:1283-94. [PMID: 21854094 DOI: 10.3109/00365521.2011.610002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
72 Zoheiry MM, Hasan SA, El-Ahwany E, Nagy FM, Taleb HA, Nosseir M, Magdy M, Meshaal S, El-Talkawy MD, Raafat I. Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma. Electron Physician 2015;7:1626-37. [PMID: 26816590 DOI: 10.19082/1626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
73 Krečak I, Gverić-Krečak V, Lapić I, Rončević P, Gulin J, Fumić K, Krečak F, Holik H, Duraković N. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms. Acta Clin Belg 2021;76:32-9. [PMID: 31455178 DOI: 10.1080/17843286.2019.1659467] [Reference Citation Analysis]
74 Salvatore V, Teti G, Bolzani S, Focaroli S, Durante S, Mazzotti MC, Falconi M. Simulating tumor microenvironment: changes in protein expression in an in vitro co-culture system. Cancer Cell Int 2014;14:40. [PMID: 24883044 DOI: 10.1186/1475-2867-14-40] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
75 Ismail H, Helby J, Hölmich LR, Chakera AH, Bastholt L, Klyver H, Sjøgren P, Schmidt H, Schöllhammer L, Johansen JS, Nordestgaard BG, Bojesen SE. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. Eur J Cancer 2019;121:74-84. [PMID: 31563729 DOI: 10.1016/j.ejca.2019.08.025] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Parnetti L, Chiasserini D. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer’s disease. Biomarkers in Medicine 2011;5:479-84. [DOI: 10.2217/bmm.11.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
77 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
78 Duraković N, Krečak I, Perić Z, Milošević M, Desnica L, Pulanić D, Pusic I, Kušec V, Vrhovac R, Pavletic SZ, Nemet D. Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity? Croat Med J 2016;57:239-46. [PMID: 27374825 DOI: 10.3325/cmj.2016.57.239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Kornblit B, Wang T, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, Müller C, Verneris MR, Müller K, Johansen JS, Vindelov L, Garred P. YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome. Bone Marrow Transplant 2016;51:1556-60. [PMID: 27427920 DOI: 10.1038/bmt.2016.192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Mørup AM, Kornblit B, Johansen JS, Masmas TN, Madsen HO, Vindeløv L, Garred P. The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2011;17:1299-307. [DOI: 10.1016/j.bbmt.2011.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
81 Zadi Heydarabad M, Baharaghdam S, Azimi A, Mohammadi H, Eivazi Ziaei J, Yazdanpanah B, Zak MS, Farahani ME, Dohrabpour A, Partash N, Talebi M. The role of tumor suppressor of resveratrol and prednisolone by downregulation of YKL-40 expression in CCRF-CEM cell line. J Cell Biochem 2019;120:3773-9. [PMID: 30426549 DOI: 10.1002/jcb.27659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Anand V, Jaswal S, Singh S, Kumar S, Jena MK, Verma AK, Yadav ML, Janjanam J, Lotfan M, Malakar D, Dang AK, Mohanty TK, Kaushik JK, Mohanty AK. Functional characterization of Mammary Gland Protein-40, a chitinase-like glycoprotein expressed during mammary gland apoptosis. Apoptosis 2016;21:209-24. [DOI: 10.1007/s10495-015-1196-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
83 Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res 2015;75:487-96. [PMID: 25511377 DOI: 10.1158/0008-5472.CAN-13-3339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
84 Michelakakis N, Neroutsos GJ, Perpinia AS, Farmakis D, Voukouti EG, Karavidas AJ, Parissis J, Georgiakaki MT, Pyrgakis VN. Chitinase-3-like protein-1 (YKL-40) before and after therapy in supraventricular arrhythmias: . Journal of Cardiovascular Medicine 2017;18:650-4. [DOI: 10.2459/jcm.0000000000000539] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
85 Eldaly MN, Metwally FM, Shousha WG, El-Saiid AS, Ramadan SS. Clinical Potentials of miR-576-3p, miR-613, NDRG2 and YKL40 in Colorectal Cancer Patients. Asian Pac J Cancer Prev 2020;21:1689-95. [PMID: 32592365 DOI: 10.31557/APJCP.2020.21.6.1689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Yan J, Shen P, Zheng J, Liu M. Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer. Ann Transl Med 2015;3:354. [PMID: 26807409 DOI: 10.3978/j.issn.2305-5839.2015.11.22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Vocka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, Zima T, Petruzelka L. Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. Oncol Lett 2019;18:6284-92. [PMID: 31788106 DOI: 10.3892/ol.2019.10925] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
88 Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2012;217:652-6. [PMID: 22209156 DOI: 10.1016/j.imbio.2011.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
89 Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 2011;412:709-12. [PMID: 21272568 DOI: 10.1016/j.cca.2011.01.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
90 Gybel-Brask D, Johansen JS, Christiansen IJ, Skibsted L, Høgdall EV. Serum YKL-40 and gestational diabetes - an observational cohort study. APMIS 2016;124:770-5. [PMID: 27457220 DOI: 10.1111/apm.12573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Lee YS, Yu JE, Kim KC, Lee DH, Son DJ, Lee HP, Jung JK, Kim ND, Ham YW, Yun J, Han SB, Hong JT. A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals. Mol Oncol 2021. [PMID: 34758182 DOI: 10.1002/1878-0261.13138] [Reference Citation Analysis]
92 Lee DH, Kim KC, Hwang CJ, Park KR, Jung YS, Kim SY, Kim JY, Song JK, Song MJ, Choi MK, Hwang DY, Han SB, Hong JT. Decreased Lung Tumor Development in SwAPP Mice through the Downregulation of CHI3L1 and STAT 3 Activity via the Upregulation of miRNA342-3p. Mol Ther Nucleic Acids 2019;16:63-72. [PMID: 30849743 DOI: 10.1016/j.omtn.2019.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
93 Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, Su L, Tian JJ, Gai ZT. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648. [PMID: 22970277 DOI: 10.1371/journal.pone.0044648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
94 Chaocharoen W, Suginta W, Limbut W, Ranok A, Numnuam A, Khunkaewla P, Kanatharana P, Thavarungkul P, Schulte A. Electrochemical detection of the disease marker human chitinase-3-like protein 1 by matching antibody-modified gold electrodes as label-free immunosensors. Bioelectrochemistry 2015;101:106-13. [PMID: 25203453 DOI: 10.1016/j.bioelechem.2014.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
95 Mistrangelo M, Senetta R, Racca P, Castellano I, Chiusa L, Bellò M, Ricardi U, Morino M, Cassoni P. A novel biomarker-based analysis reliably predicts nodal metastases in anal carcinoma: preliminary evidence of therapeutic impact. Colorectal Dis 2013;15:1382-91. [PMID: 23692332 DOI: 10.1111/codi.12289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 Aam BB, Heggset EB, Norberg AL, Sørlie M, Vårum KM, Eijsink VG. Production of chitooligosaccharides and their potential applications in medicine. Mar Drugs 2010;8:1482-517. [PMID: 20559485 DOI: 10.3390/md8051482] [Cited by in Crossref: 382] [Cited by in F6Publishing: 337] [Article Influence: 31.8] [Reference Citation Analysis]
97 Hamilton G, Rath B, Ulsperger E. How to target small cell lung cancer. Oncoscience 2015;2:684-92. [PMID: 26425658 DOI: 10.18632/oncoscience.212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
98 Hermansson L, Yilmaz A, Axelsson M, Blennow K, Fuchs D, Hagberg L, Lycke J, Zetterberg H, Gisslén M. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation 2019;16:16. [PMID: 30678707 DOI: 10.1186/s12974-019-1404-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
99 Urbanavičiūtė R, Zabitaitė R, Kriščiukaitis A, Deltuva VP, Skiriutė D. Serum protein triplet TGF-β1, TIMP-1, and YKL-40 serve as diagnostic and prognostic profile for astrocytoma. Sci Rep 2021;11:13100. [PMID: 34162919 DOI: 10.1038/s41598-021-92328-3] [Reference Citation Analysis]
100 Steponaitis G, Skiriutė D, Kazlauskas A, Golubickaitė I, Stakaitis R, Tamašauskas A, Vaitkienė P. High CHI3L1 expression is associated with glioma patient survival. Diagn Pathol 2016;11:42. [PMID: 27121858 DOI: 10.1186/s13000-016-0492-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
101 Lee SH, Lin CY, Wang PH, Han CP, Yang SF, Chang JT, Lee MC, Lin LY, Lee MS. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease. J Clin Lab Anal 2012;26:136-42. [PMID: 22628227 DOI: 10.1002/jcla.21500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
102 Chen HY, Zhou ZY, Luo YL, Luo Q, Fan JT. Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer. Cell Biol Int 2021. [PMID: 34498339 DOI: 10.1002/cbin.11699] [Reference Citation Analysis]
103 d'Abramo C, D'Adamio L, Giliberto L. Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. J Pers Med 2020;10:E116. [PMID: 32911755 DOI: 10.3390/jpm10030116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
104 Fantino E, Gangell CL, Hartl D, Sly PD; AREST CF. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med 2014;14:28. [PMID: 24576297 DOI: 10.1186/1471-2466-14-28] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
105 Leonardi S, Parisi GF, Capizzi A, Manti S, Cuppari C, Scuderi MG, Rotolo N, Lanzafame A, Musumeci M, Salpietro C. YKL-40 as marker of severe lung disease in cystic fibrosis patients. Journal of Cystic Fibrosis 2016;15:583-6. [DOI: 10.1016/j.jcf.2015.12.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
106 Chaocharoen W, Schulte A, Suginta W. hYKL-40 cancer biomarker electroanalysis in serum samples and model cell lysates: capacitive immunosensing compared with enzyme label immunosorbent assays (ELISA). Analyst 2017;142:503-10. [DOI: 10.1039/c6an02239a] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
107 Qureshi AM, Hannigan A, Campbell D, Nixon C, Wilson JB. Chitinase-like proteins are autoantigens in a model of inflammation-promoted incipient neoplasia. Genes Cancer. 2011;2:74-87. [PMID: 21779482 DOI: 10.1177/1947601911402681] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
108 Di Rosa M, Malaguarnera G, De Gregorio C, Drago F, Malaguarnera L. Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages. Inflammation. 2013;36:482-492. [PMID: 23149946 DOI: 10.1007/s10753-012-9569-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]